Pegozafermin - 89bio
Alternative Names: BIO-89-100; TEV 47948Latest Information Update: 28 Sep 2024
Price :
$50 *
At a glance
- Originator Teva Pharmaceutical Industries
- Developer 89bio
- Class Antihyperlipidaemics; Antineoplastics; Fibroblast growth factors; Hepatoprotectants; Polyethylene glycols; Recombinant proteins
- Mechanism of Action Fibroblast growth factor 21 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Hypertriglyceridaemia; Non-alcoholic steatohepatitis
- Phase I/II Non-alcoholic fatty liver disease
- Preclinical Liver cancer
Most Recent Events
- 28 Sep 2024 No recent reports of development identified for phase-I development in Non-alcoholic-steatohepatitis in USA (SC, Liquid)
- 07 Aug 2024 89Bio announces intention to launch Pegozafermin
- 10 Jun 2024 Phase-III clinical trials in Hypertriglyceridaemia in India, Italy (SC) (NCT05852431)